Compare · NVO vs RGNT
NVO vs RGNT
Side-by-side comparison of Novo Nordisk A/S (NVO) and Regentis Biomaterials Ltd. (RGNT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. NVO focuses on Biotechnology: Pharmaceutical Preparations, while RGNT focuses on Industrial Specialties.
- NVO is the larger of the two at $180.22B, about 21030.8x RGNT ($8.6M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 2 for RGNT).
- NVO has more recent analyst coverage (25 ratings vs 0 for RGNT).
- Company
- Novo Nordisk A/S
- Regentis Biomaterials Ltd.
- Price
- -
- -
- Market cap
- $180.22B
- $8.6M
- 1M return
- +5.96%
- -
- 1Y return
- -14.37%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Industrial Specialties
- Exchange
- NYSE
- AMEX
- IPO
- 2025
- News (4w)
- 9
- 2
- Recent ratings
- 25
- 0
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest RGNT
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Signs Exclusive Distribution Agreement with AMI Technologies to Commercialize GelrinC(R) in Israel
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
- Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
- SEC Form EFFECT filed by Regentis Biomaterials Ltd.
- IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
- SEC Form POS AM filed by Regentis Biomaterials Ltd.
- SEC Form 6-K filed by Regentis Biomaterials Ltd.
- Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update